Acute symptomatic seizures occurring in close temporal relationship with an acute CNS insult are distinct from epilepsy and occur frequently in clinical practice. The aim of this educational review is to provide information on the most important aspects related to acute symptomatic seizures that will allow clinicians to accurately distinguish acute symptomatic seizures from epilepsy in their patients. We explain the definition of acute symptomatic seizures and we illustrate how acute symptomatic seizures differ from epilepsy. We describe acute symptomatic seizures in the context of their various underlying aetiologies and we discuss the approach to the management of patients with acute symptomatic seizures.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1684/epd.2021.1376 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease.
Stroke
January 2025
Population Health Research Institute, University of British Columbia, Vancouver, Canada. (M.A.S., J.W.E., A.H.K., A. Shoamanesh, A.T., R.G.H., A.C., R.Z.).
Background: Stroke secondary to intracranial atherosclerotic disease (ICAD) is associated with high recurrence risk despite currently available secondary prevention strategies. In patients with systemic atherosclerosis, a significant reduction of stroke risk with no increase in intracranial or fatal hemorrhage was seen when rivaroxaban 2.5 mg twice daily was added to aspirin.
View Article and Find Full Text PDFStatin therapy in ischemic stroke patients with atrial fibrillation: Efficacy and safety outcomes.
Eur Stroke J
January 2025
Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Perugia, Italy.
Introduction: The efficacy and safety of statins for secondary prevention in patients who have experienced a cardioembolic stroke are not well-defined. However, previous observational data reported hyperlipidemia as a risk factor for both ischemic and bleeding complications in patients with AF and previous stroke. Based on these premises, we conducted a sub-analysis of the RAF and RAF-NOAC studies to evaluate the efficacy and safety of statins in secondary prevention in patients with acute ischemic stroke and AF.
View Article and Find Full Text PDFA case of pityriasis rubra pilaris secondary to ponatinib.
SAGE Open Med Case Rep
January 2025
Departement of Dermatology, Charles-Le Moyne Hospital, Longueuil, QC, Canada.
Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. In this case, a 63-year-old woman developed a pityriasis rubra pilaris-like eruption 1 month after starting the drug. The skin reaction improved with dose reduction and recurred more mildly at a lower dose.
View Article and Find Full Text PDFBurden of disease of respiratory syncytial virus in older adults and adults considered at high risk of severe infection.
Can Commun Dis Rep
January 2025
Public Health Agency of Canada, Ottawa, ON.
Background: Availability of new vaccines for adults has increased interest in understanding Canada's respiratory syncytial virus (RSV) burden in older adults and adults considered at high risk of severe infection.
Objective: To characterize the burden of RSV disease in Canada by joint analysis of the published literature and hospitalization data from a healthcare administrative database.
Methods: Electronic databases of published literature were searched to identify studies and systematic reviews reporting data on outpatient visits, hospitalizations, intensive care unit (ICU) admissions and deaths associated with RSV infection in adults.
Risk prediction model for poor prognosis after intravenous thrombolysis among ischemic stroke patients aged ≥ 80 years and analysis of follow-up.
Sci Rep
January 2025
Department of Neurology, The Second Hospital of Dalian Medical University, No. 467 Zhongshan Road, Shahekou District, Dalian City, 116023, Liaoning, China.
To develop and validate practical prediction tools to estimate poor outcomes in patients ≥ 80 years old with acute ischemic stroke after intravenous alteplase thrombolysis, aiding clinical decision-making.To explore the longest benefit window after thrombolysis in the elderly. 1: A retrospectively analysis was conducted on acute stroke patients who underwent intravenous thrombolysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!